Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.
about
Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infectionsAcinetobacter baumannii: evolution of antimicrobial resistance-treatment optionsIdentification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestrationEpidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipientsRisk Factors, Clinical Presentation, and Outcome of Acinetobacter baumannii Bacteremia.Epidemiological characterizations of class 1 integrons from multidrug-resistant acinetobacter isolates in Daejeon, Korea.Epidemiology and clonality of carbapenem-resistant Acinetobacter baumannii from an intensive care unit in Palermo, ItalyPredictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study.Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance.Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.Recurrent bacteremia caused by the Acinetobacter calcoaceticus-Acinetobacter baumannii complex.Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.).Therapeutic options for Acinetobacter baumannii infections: an update.Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.Efficacy and Safety of High Loading Dose of Colistin in Multidrug-Resistant Acinetobacter baumannii: A Prospective Cohort Study.Efficacy of Trans-cinnamaldehyde and Eugenol in Reducing Acinetobacter baumannii Adhesion to and Invasion of Human Keratinocytes and Controlling Wound Infection In Vitro.Prevalence of Multidrug-Resistant Bacteria on Fresh Vegetables Collected from Farmers' Markets in Connecticut.Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis.Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study.Acinetobacter baumannii infection in solid organ transplant recipients.In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.Anti-inflammatory and anti-superbacterial activity of polyphenols isolated from black raspberry.Pathogenicity of clinical Acinetobacter baumannii isolates in a Galleria mellonella host model according to bla(OXA-40) gene and epidemiological outbreak status.Acinetobacter baumannii infections in a tertiary care hospital in Mexico over the past 13 years.The deadly impact of extreme drug resistance in Acinetobacter baumannii.Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort.Prevalence of Acinetobacter baumannii bacteremia in intensive care units of Ibn Rochd University Hospital, Casablanca.Trans-Cinnamaldehyde and Eugenol Increase Acinetobacter baumannii Sensitivity to Beta-Lactam Antibiotics.Changes in Antimicrobial Usage Patterns in Korea: 12-Year Analysis Based on Database of the National Health Insurance Service-National Sample Cohort
P2860
Q26991886-D2A18483-8433-4B75-82CD-C9BDDC4892E1Q27015109-AF4F769D-DC55-41E8-A8D8-418D55172D45Q27339544-E96B8CF6-71CC-4936-8043-FCDE1030FF38Q28484482-BD848455-F1A7-413A-9274-47DBEB217F4CQ33633989-66B71019-C4F0-413D-B61E-3E6013955610Q33807604-34300251-E4B9-4537-A3D3-8ACCE7848E42Q34346675-C29A1657-BBEC-434B-BDD2-15733DDB3D18Q34437954-5731AC92-0775-47E2-9EA0-005A797FC4CDQ34974577-55A5C32F-4EDF-4D27-A96E-FDD4AB7D3323Q34995782-1A801B04-8DD8-4DEC-828F-E11A6DAC5979Q35222421-8484BCA7-FB97-43F8-B3C7-03BC80480E15Q36172180-412FF8D9-0911-4766-84A2-9C43F2A75AFCQ36887794-3F9A7A74-7BFE-44FE-B860-22DE83B4A838Q37364437-196DE362-B9CE-4062-B1D6-7268C3927C00Q38049332-B8FCA5D1-CDE5-4E28-B847-4D0D88937F71Q38416932-6C6F3687-3ECF-4D32-8A29-593348B8C958Q39038590-515E50FB-44B7-4D49-B293-D0C545C719C6Q40088667-EDE1B862-6D3B-4FCC-8DAC-B1C2FF31389CQ40543317-31FC1EEF-6D1C-4A8C-BFE4-99B1D1FBF5A1Q40586092-2474F4F7-E2F7-4325-BDAB-F41C17BEB56BQ40612894-0395B1AF-823E-4F2F-943A-AF50BD439CFFQ41091116-9FA9D568-5515-45EC-A214-5C149280E703Q41549501-037D98E1-9CF6-4F43-A712-1A78D2939D05Q41833657-F2A5A943-5737-4296-92ED-D90CB0FB22FEQ41863895-22B38A5F-F443-49B3-BE71-2A62C1FE0CAFQ41907650-902F12F2-FA7D-41BF-B7C8-9E96C5B4D964Q42255792-A341CF84-FA4F-4DF2-8D9A-549201B34195Q42575612-4C966643-74FD-47BD-8E41-6E05FB8B9D1CQ46198938-CB7512DA-2FF7-492C-81CA-312523E2AB3FQ50318336-7AB088AF-14A9-4323-8C73-9D1A9D398797Q55260699-35616C51-51E0-491A-B4FB-FBB064743187Q57213780-39048E55-593D-4777-9AC2-569991285874
P2860
Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of carbapenem resistanc ...... mannii bloodstream infections.
@ast
Impact of carbapenem resistanc ...... mannii bloodstream infections.
@en
type
label
Impact of carbapenem resistanc ...... mannii bloodstream infections.
@ast
Impact of carbapenem resistanc ...... mannii bloodstream infections.
@en
prefLabel
Impact of carbapenem resistanc ...... mannii bloodstream infections.
@ast
Impact of carbapenem resistanc ...... mannii bloodstream infections.
@en
P2093
P2860
P356
P1476
Impact of carbapenem resistanc ...... umannii bloodstream infections
@en
P2093
John S Esterly
Michael J Postelnick
Michael Malczynski
Milena Griffith
P2860
P304
P356
10.1128/AAC.01728-10
P407
P577
2011-08-08T00:00:00Z